Clinical trial
Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis
NCT00195507 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195507 |
|---|---|
| Title | Study Evaluating Etanercept in the Treatment of Subjects With Psoriasis |
| Official title | A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 720 |
| Start date | Dec 1, 2004 |
| Completion | Feb 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 25, 2013 |
| Countries | Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway and 7 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: